Last reviewed · How we verify

NCT05448339

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

Completed Last updated 9 January 2024
What this trial tests

trial testing PVHA or TACE in Liver Transplantation in 197 participants. Completed in 1 January 2024.

Timeline
1 January 2013
Primary endpoint
31 December 2023
1 January 2024

Quick facts

Lead sponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
StatusCompleted
Study typeOBSERVATIONAL
Enrollment197
Start date1 January 2013
Primary completion31 December 2023
Estimated completion1 January 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 65, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05448339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing